Virbac is an independent pharmaceutical company founded in 1968 and exclusively dedicated to animal health. The company develops veterinary pharmaceuticals, vaccines, diagnostics, and solutions across parasitology, dermatology, and antibiotics. Its product portfolio serves veterinarians, farmers, and pet owners, covering more than 50 animal species.
The firm employs more than 5,100 people globally and operates 33 sales subsidiaries, production facilities in 10 countries, and R&D centres in 7 countries including the United States, France, Vietnam, and Australia. Its presence spans over 100 countries, making it the 6th largest veterinary biopharma group in the world. Virbac has been listed on the Paris Stock Exchange since 1985.
Technologists at Virbac work across a broad domain: from vaccine development and molecular diagnostics to data-driven parasitology and dermatology research. With R&D centres in the US, Mexico, Chile, Uruguay, France, Vietnam, and Australia, engineering and science roles involve building and maintaining platforms that support pharmaceutical discovery, regulatory compliance, and global distribution at scale.
The company remains family-owned, with the founder's family retaining a majority of voting rights. Its stated focus is on prevention and the well-being of animals, supported by scientifically backed and innovative solutions.
